<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519671</url>
  </required_header>
  <id_info>
    <org_study_id>CCF-Stem Cells IBD-001</org_study_id>
    <nct_id>NCT04519671</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease</brief_title>
  <acronym>PFCD</acronym>
  <official_title>A Phase IB/IIA Study of Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amy Lightner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of using adult allogeneic&#xD;
      bone marrow derived mesenchymal stem cells (MSCs), to treat people for medically refractory&#xD;
      perianal fistulizing Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Crohn's disease (CD), a chronic transmural inflammatory disease of the gastrointestinal&#xD;
      tract, continues to increase in incidence for unknown reasons. According to population based&#xD;
      studies, at least 26% of patients with CD will develop perianal fistulas in the first two&#xD;
      decades following diagnosis, particularly those with colonic and rectal involvement. These&#xD;
      patients experience significant morbidity due to pain, persistent drainage, recurrent&#xD;
      perianal sepsis, and ongoing need to access medical care resulting in increased costs and&#xD;
      impaired quality of life.&#xD;
&#xD;
      Unfortunately, perianal fistulizing Crohn's disease is notoriously difficult to cure with 37%&#xD;
      of patients experiencing refractory disease. As a result, patients cycle through numerous&#xD;
      immunosuppressive medications that can have significant side effects, and &gt;90% undergo&#xD;
      multiple surgical interventions putting them at risk of incontinence.&#xD;
&#xD;
      The specific rationale for MSCs in perianal Crohn's fistulas is based upon 1) their&#xD;
      anti-inflammatory and immunomodulatory properties; 2) several studies reporting the safety&#xD;
      and efficacy of MSCs for the treatment of perianal Crohn's fistula; 3) existence of safe&#xD;
      manufacturing methods for isolation and expansion of MSCs.&#xD;
&#xD;
      This study will enroll 20 participants that have Crohn's disease with medically and&#xD;
      surgically refractory perianal fistulizing disease. Participants enrolled will be those that&#xD;
      meet particular criteria for participation in the clinical trial.&#xD;
&#xD;
      Enrolled participants will be randomized to treatment group with adult allogeneic bone marrow&#xD;
      derived mesenchymal stem cells, versus placebo in a 3:1 fashion. Participants in the&#xD;
      treatment group will have a direct injection of MSCs at a dose of 75 million cells. This will&#xD;
      be given as a direct injection in and around the fistula tract. Participants will be&#xD;
      evaluated for complete healing at three months. If complete healing has been achieved,&#xD;
      participants will continue to be followed for one year. If complete healing has not been&#xD;
      achieved at three months, participants will be eligible for a second injection of MSCs at the&#xD;
      same dose of 75 million cells. Control participants without complete healing from placebo&#xD;
      will cross over at the 6 month visit to receive an injection of MSCs and again three months&#xD;
      after this as above, and will be followed for one year after treatment to a total duration of&#xD;
      18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related adverse events</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of participants with treatment related adverse events post-injection of 75 million allogeneic bone marrow derived MSC's for the treatment of perianal fistula(s) in the setting of Crohn's disease as assessed by protocol CCF-Stem Cells IBD-001</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete clinical healing</measure>
    <time_frame>Month 6, Month 12</time_frame>
    <description>Number of participants with complete clinical healing post-injection of 75 million allogeneic bone marrow derived MSC's for the treatment of perianal fistula(s) in the setting of Crohn's disease.&#xD;
Complete Healing is defined as:&#xD;
Radiographic Healing: MRI with an absence of a fluid collection &gt;2 cm in 3 of 3 dimensions, lack of edema, inflammation or sign of active inflammatory response. A remnant scar of a fistula tract may remain&#xD;
Clinical Healing: 100% cessation of drainage on both clinical exam with deep palpation and per patient report and epithelization of the external fistula opening</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Partial clinical healing</measure>
    <time_frame>Month 6, Month 12</time_frame>
    <description>Number of participants with partial clinical healing post-injection of 75 million allogeneic bone marrow derived MSC's for the treatment of perianal fistula(s) in the setting of Crohn's disease&#xD;
Partial clinical healing is defined as:&#xD;
Radiographic Healing: MRI with an absence of a fluid collection &gt;2 cm in 2 of 3 dimensions, lack of edema, inflammation or sign of active inflammatory response. A remnant scar of a fistula tract may remain&#xD;
Clinical healing: Greater than or equal to 50 % cessation of drainage on both clinical exam with deep palpation and per patient report and epithelization of the external fistula opening</description>
  </other_outcome>
  <other_outcome>
    <measure>Lack of response</measure>
    <time_frame>Month 6, Month 12</time_frame>
    <description>Number of participants with lack of response post-injection of 75 million allogeneic bone marrow derived MSC's for the treatment of perianal fistula(s) in the setting of Crohn's disease&#xD;
Lack of response is defined as:&#xD;
Radiographic and Clinical healing which does not meet the threshold for Partial Healing</description>
  </other_outcome>
  <other_outcome>
    <measure>Worsening of disease</measure>
    <time_frame>Month 6, Month 12</time_frame>
    <description>Number of participants with worsening of disease post-injection of 75 million allogeneic bone marrow derived MSC's for the treatment of perianal fistula(s) in the setting of Crohn's disease&#xD;
Worsening disease is defined as:&#xD;
Radiographic: MRI with a fluid collection &gt;2 cm in 2 of 3 dimensions, edema, inflammation or sign of active inflammatory response. An increased number of tracts may be seen, or increased branching from the primary tract,&#xD;
Clinical: Increased drainage per patient report and on clinical exam</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Perianal Crohn Disease</condition>
  <condition>Perianal Fistula</condition>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Mesenchymal Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesenchymal Stem Cells</intervention_name>
    <description>Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s)</description>
    <arm_group_label>Mesenchymal Stem Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Men and Women 18-75 years of age with a diagnosis of Crohn's disease for at least six&#xD;
             months duration.&#xD;
&#xD;
          2. Single and Multi-tract Perianal fistula, with or without previous failed surgical&#xD;
             repair.&#xD;
&#xD;
          3. Have no contraindications to MR evaluations: e.g. pacemaker or magnetically active&#xD;
             metal fragments, claustrophobia&#xD;
&#xD;
          4. Ability to comply with protocol&#xD;
&#xD;
          5. Competent and able to provide written informed consent&#xD;
&#xD;
          6. Concurrent Crohn's-related therapies with stable doses corticosteroids, 5- ASA drugs,&#xD;
             immunomodulators, anti-TNF therapy, anti-integrin and anti-interleukin therapies are&#xD;
             permitted.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Inability to give informed consent.&#xD;
&#xD;
          2. Clinically significant medical conditions within the six months before administration&#xD;
             of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other&#xD;
             conditions that would, in the opinion of the investigators, compromise the safety of&#xD;
             the patient.&#xD;
&#xD;
          3. Specific exclusions:&#xD;
&#xD;
               1. Hepatitis B or C&#xD;
&#xD;
               2. HIV&#xD;
&#xD;
               3. Abnormal AST or ALT at screening&#xD;
&#xD;
          4. History of cancer including melanoma (with the exception of localized skin cancers) in&#xD;
             the past five years&#xD;
&#xD;
          5. Investigational drug within one month of treatment&#xD;
&#xD;
          6. Pregnant or breast feeding or trying to become pregnant.&#xD;
&#xD;
          7. Presence of a rectovaginal or perineal body fistula&#xD;
&#xD;
          8. Change in Crohn's immunosuppressive regimen within the 2 months prior to enrollment&#xD;
&#xD;
          9. Uncontrolled intestinal Crohn's disease which will require escalation for medical&#xD;
             therapy or surgery within 2 months of enrollment&#xD;
&#xD;
         10. Severe anal canal disease that is stenotic and requires dilation&#xD;
&#xD;
         11. Currently taking corticosteroids&#xD;
&#xD;
         12. Female participant unwilling to agree to use acceptable contraception methods during&#xD;
             participation in study&#xD;
&#xD;
         13. Allergy to DMSO&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Lightner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kavita Elliott, BS</last_name>
    <phone>216-403-3573</phone>
    <email>ibdstemcelltherapy@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Matyas, BS</last_name>
    <phone>216-212-0746</phone>
    <email>ibdstemcelltherapy@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kavita Elliott</last_name>
    </contact>
    <contact_backup>
      <last_name>Caroline Matyas</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kasparek MS, Glatzle J, Temeltcheva T, Mueller MH, Koenigsrainer A, Kreis ME. Long-term quality of life in patients with Crohn's disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum. 2007 Dec;50(12):2067-74.</citation>
    <PMID>17680311</PMID>
  </reference>
  <reference>
    <citation>Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003 Nov;125(5):1508-30. Review.</citation>
    <PMID>14598268</PMID>
  </reference>
  <reference>
    <citation>Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002 Apr;122(4):875-80.</citation>
    <PMID>11910338</PMID>
  </reference>
  <reference>
    <citation>Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016 Sep 24;388(10051):1281-90. doi: 10.1016/S0140-6736(16)31203-X. Epub 2016 Jul 29.</citation>
    <PMID>27477896</PMID>
  </reference>
  <reference>
    <citation>Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2018 Apr;154(5):1334-1342.e4. doi: 10.1053/j.gastro.2017.12.020. Epub 2017 Dec 24.</citation>
    <PMID>29277560</PMID>
  </reference>
  <reference>
    <citation>Molendijk I, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Dijkstra G, van der Woude CJ, Duijvestein M, Veenendaal RA, Zwaginga JJ, Verspaget HW, Fibbe WE, van der Meulen-de Jong AE, Hommes DW. Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2015 Oct;149(4):918-27.e6. doi: 10.1053/j.gastro.2015.06.014. Epub 2015 Jun 25.</citation>
    <PMID>26116801</PMID>
  </reference>
  <reference>
    <citation>Molendijk I, van der Meulen-de Jong AE, Verspaget HW, Veenendaal RA, Hommes DW, Bonsing BA, Peeters KCMJ. Standardization of mesenchymal stromal cell therapy for perianal fistulizing Crohn's disease. Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1148-1154. doi: 10.1097/MEG.0000000000001208.</citation>
    <PMID>30095479</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Amy Lightner</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>perianal fistula</keyword>
  <keyword>perianal Crohn's disease</keyword>
  <keyword>mesenchymal stromal cells</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

